The use of primary mesenchymal stem cells (MSCs) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSCs)-derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these agiing-associated drawbacks.